| Literature DB >> 28994409 |
Simon Boje Hansen1, Nick Stub Laursen1, Gregers Rom Andersen1, Kasper R Andersen1.
Abstract
The generation of high-quality protein crystals and the loss of phase information during an X-ray crystallography diffraction experiment represent the major bottlenecks in the determination of novel protein structures. A generic method for introducing Hg atoms into any crystal independent of the presence of free cysteines in the target protein could considerably facilitate the process of obtaining unbiased experimental phases. Nanobodies (single-domain antibodies) have recently been shown to promote the crystallization and structure determination of flexible proteins and complexes. To extend the usability of nanobodies for crystallographic work, variants of the Nb36 nanobody with a single free cysteine at one of four framework-residue positions were developed. These cysteines could be labelled with fluorophores or Hg. For one cysteine variant (Nb36-C85) two nanobody structures were experimentally phased using single-wavelength anomalous dispersion (SAD) and single isomorphous replacement with anomalous signal (SIRAS), taking advantage of radiation-induced changes in Cys-Hg bonding. Importantly, Hg labelling influenced neither the interaction of Nb36 with its antigen complement C5 nor its structure. The results suggest that Cys-Hg-labelled nanobodies may become efficient tools for obtaining de novo phase information during the structure determination of nanobody-protein complexes.Entities:
Keywords: SAD; SIRAS; mercury; nanobodies; phasing; single isomorphous replacement with anomalous signal; single-wavelength anomalous dispersion
Mesh:
Substances:
Year: 2017 PMID: 28994409 PMCID: PMC5633906 DOI: 10.1107/S2059798317013171
Source DB: PubMed Journal: Acta Crystallogr D Struct Biol ISSN: 2059-7983 Impact factor: 7.652
Figure 1Site-specific labelling of Nbs. (a) Overview of a Nb structure (exemplified here by PDB entry 3p0g; Rasmussen et al., 2011 ▸) with the face in red observed to contribute to antigen binding (potential binding face); the face in blue has never been observed to directly interact during antigen binding (free face). The positions of the four Ser-to-Cys mutations are indicated as yellow spheres on the free face of the Nb. (b) Nonreduced SDS–PAGE of the labelling reactions with the dimeric form of Nb36 (*) and MPEG-labelled Nb36 (**) indicated. (c) Quantification of labelling efficiency based on the MPEG–maleimide assay. (d) Alexa Fluor 488 labelling of the four cysteine-mutated Nbs. Nonreduced SDS–PAGE analysis of labelled and unlabelled Nbs (top) and the corresponding fluorescence scan of the gel (bottom). * indicates the fraction of dimeric Nb36 nonspecifically labelled with Alexa Fluor 488.
Data-collection and refinement statistics
Values in parentheses are for the highest resolution shell.
| Nb36-Nat1 | Nb36-Nat2 | Nb36-C85-1 | Nb36-C85-2 | |
|---|---|---|---|---|
| PDB code |
|
|
|
|
| Beamline | I04, DLS | BioMAX, MAX IV | P13, PETRA | ID23, ESRF |
| Wavelength (Å) | 0.9686 | 0.9796 | 1.008 | 1.008 |
| Resolution range (Å) | 29.3–1.193 (1.236–1.193) | 28.81–1.499 (1.553–1.499) | 71.25–1.50 (1.554–1.500) | 45.41–2.50 (2.589–2.500) |
| Space group |
|
|
|
|
| Unit-cell parameters | ||||
|
| 102.56 | 101.86 | 37.61 | 83.96 |
|
| 29.27 | 30.04 | 93.07 | 99.11 |
|
| 33.13 | 32.89 | 142.51 | 85.41 |
| α (°) | 90 | 90 | 90 | 90 |
| β (°) | 97.011 | 90.837 | 90 | 105.772 |
| γ (°) | 90 | 90 | 90 | 90 |
| Total reflections | 203833 (10799) | 51526 (3091) | 521268 (48924) | 268259 (11613) |
| Unique reflections | 30668 (2451) | 15233 (1123) | 81018 (7976) | 43707 (3010) |
| Multiplicity | 6.6 (4.4) | 3.4 (2.7) | 6.4 (6.1) | 6.1 (3.9) |
| Completeness (%) | 97.67 (78.67) | 93.81 (70.34) | 99.80 (99.89) | 93.59 (64.95) |
| Mean | 10.65 (1.15) | 10.26 (1.06) | 17.44 (1.57) | 14.38 (0.80) |
| Wilson | 15.87 | 25.95 | 22.30 | 67.63 |
|
| 0.08345 (1.022) | 0.05309 (0.7674) | 0.05807 (1.111) | 0.08839 (1.5) |
|
| 0.09057 (1.153) | 0.06285 (0.936) | 0.06328 (1.214) | 0.09642 (1.743) |
|
| 0.03457 (0.5135) | 0.03297 (0.5247) | 0.02482 (0.4852) | 0.0379 (0.8658) |
| CC1/2 | 0.998 (0.496) | 0.998 (0.399) | 0.999 (0.641) | 0.998 (0.185) |
| CC* | 0.999 (0.814) | 1 (0.755) | 1 (0.884) | 1 (0.559) |
| Reflections used in refinement | 30641 (2445) | 15222 (1122) | 81007 (7975) | 43704 (3010) |
| Reflections used for | 1998 (159) | 1529 (111) | 2018 (202) | 2014 (132) |
|
| 0.1750 (0.4562) | 0.1992 (0.3669) | 0.1886 (0.3065) | 0.2239 (0.3770) |
|
| 0.1979 (0.5825) | 0.2484 (0.3749) | 0.2114 (0.3066) | 0.2617 (0.3639) |
| CCwork | 0.970 (0.677) | 0.963 (0.666) | 0.955 (0.817) | 0.932 (0.400) |
| CCfree | 0.976 (0.590) | 0.934 (0.663) | 0.949 (0.764) | 0.928 (0.342) |
| No. of non-H atoms | ||||
| Total | 1046 | 965 | 3864 | 8487 |
| Protein | 902 | 887 | 3483 | 8462 |
| Ligands | 5 | 5 | 2 | 25 |
| Solvent | 139 | 73 | 379 | |
| Protein residues | 118 | 117 | 462 | 1128 |
| R.m.s.d., bonds (Å) | 0.008 | 0.002 | 0.004 | 0.003 |
| R.m.s.d., angles (°) | 1.03 | 0.49 | 0.78 | 0.70 |
| Ramachandran favoured (%) | 99.14 | 97.39 | 96.90 | 97.81 |
| Ramachandran allowed (%) | 0.86 | 2.61 | 2.21 | 1.73 |
| Ramachandran outliers (%) | 0.00 | 0.00 | 0.88 | 0.46 |
| Rotamer outliers (%) | 3.00 | 2.04 | 2.11 | 3.18 |
| Clashscore | 4.43 | 1.69 | 4.18 | 3.69 |
| Average | ||||
| Overall | 21.66 | 40.15 | 31.33 | 84.93 |
| Protein | 20.47 | 40.00 | 30.68 | 84.92 |
| Ligands | 20.31 | 29.45 | 38.53 | 86.82 |
| Solvent | 29.37 | 42.72 | 37.28 | |
| No. of TLS groups | 1 | 1 | 4 | 10 |
Figure 2SAD- and SIRAS-based structure determination in P212121. (a) Electron density calculated from SAD phases based on the 1–180° data together with the final Nb36-C85-1 model. (b) As in (a) but after density modification. (c) The map calculated with SIRAS phases prepared using the 1–180° data as a derivative with anomalous signal and the 180–720° wedge as native data. (d) As in (c) but after density modification. (a)–(d) are contoured at 1.2σ. (e) Close-up of a Hg atom inserted between two NCS-related Cys85 side chains together with an anomalous map calculated with the anomalous differences from the 1–180° data and phases derived from the final model with Hg atoms and water molecules omitted. One minor site (marked with an asterisk) is already present in this wedge of data. (f) Anomalous map calculated from the anomalous differences in the 180–720° data revealing how the Hg site is splitting into one major and two minor sites. (g) Difference mF o− DF c map calculated after omission of the Hg atoms and all water molecules from the final model based on the 1–180° data. The maps in (e) and (f) are contoured at 5σ, while the difference map in (g) is displayed at 3σ. Water molecules are shown as red spheres.
Figure 3SAD-based structure determination in P21. (a) Electron density calculated from density-modified SAD phases around the CDR loops of the final Nb36-C85-2 model. (b) As in (a) but displaying the final 2mF o − DF c map. (a) and (b) are contoured at 1.2σ. (c) Close-up of the double conformation of a Cys side chain bound to a Hg atom together with a map calculated from the anomalous differences and phases derived from the final model with Hg atoms omitted. The two sites were modelled with occupancies of 0.6 and 0.4, respectively, and the map is contoured at 6σ. (d) Anomalous map calculated as in (c) around two Cys85 side chains each bound to one Hg atom. The S atom of one of these cysteines apparently also forms a nonbonded interaction (dotted blue line) with the neighbouring Hg. The map is contoured at 16σ and comparison with (c) justifies that both Hg sites are modelled with full occupancy. (e) Difference mF o − DF c map from the final model contoured at 4σ (green) and −4σ (red) of the same two Hg atoms and cysteines further supporting this interpretation.
Figure 4The structure and antigen binding is not perturbed by the Ser85Cys mutation. (a) Overlay of the 16 different Nb36 molecules present in the four different crystals, with CDR1, CDR2 and CDR3 coloured red, green and yellow, respectively. (b) Structural superposition of native Nb36-Nat1 (light blue) and PCMB-labelled Nb36-C85-1 (dark blue). (c, d) Binding of the C5 antigen to immobilized native Nb36 or PCMB-labelled Nb36-C85 measured by biolayer interferometry. The experimental association and dissociation curves are shown in black and the fitted curves are shown in blue.